ArticleInternational journal of nanomedicine2025
Novel Antigen-Presenting Cell-Targeted Nanoparticles Enhance Split Vaccine Immunity Through Microneedles Inoculation.
Article in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Microneedles in biomedicine: Innovations, challenges, and future prospects.Biomaterials translational · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim/Background: Despite their superior safety and widespread use, split vaccines typically suffer from reduced immunogenicity due to the lack of an intact viral structure. Targeting the mannose receptors on antigen-presenting cells (APCs) with nanoparticles (NPs) and delivering them via microneedles (MNs) offers a promising solution. We designed and synthesized NPs that could form complexes with split H1N1 antigens, and evaluated the immunogenicity after loading them into dissolvable microneedle arrays (dMAs). Methods: Man-N-HACC was synthesized by conjugating mannose moieties to N-2-hydroxypropyl trimethyl ammonium chloride chitosan (N-HACC), followed by cross-linking with tripolyphosphate to form Man-N-HACC NPs. The NPs were characterized in terms of morphology, size, zeta potential, spatial orientation, macrophage internalization, and stability. The microstructure, mechanical strength, skin penetration capability, and release behavior of dMAs loaded with Man-N-HACC NPs/H1N1 complexes were investigated. Finally, the efficacy of dMAs was assessed in a rat model using ELISA and hemagglutination inhibition (HAI) assay. Results: Characterization via Fourier transform infrared spectroscopy and nuclear magnetic resonance confirmed the synthesis of Man-N-HACC. The cross-linked generated Man-N-HACC NPs displayed uniform morphology and good stability over 28 days, along with confirmed spatial orientation of mannose ligands and macrophage internalization. The dMAs loaded with Man-N-HACC NPs/H1N1 exhibited mechanical robustness, capable of fully penetrating the skin and releasing nanovaccines. The increase in HAI titers and total IgG antibody levels in rat serum indicates the effectiveness of humoral immunity, and this effect only occurs after NPs formed post-crosslinking, rather than directly using raw nanomaterials, highlighting the critical role of the nanoparticle structure. Conclusion: This study confirms that the delivery of Man-N-HACC NPs via dMAs provides a novel and promising approach for the administration of split influenza vaccines. Moreover, it underscores the great potential of nano-adjuvants in enhancing the efficacy of split vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.